National Cancer Institute "Cancer Moonshot Biobank"
Recruiting
1,600 enrolled
PRO-ACTIVE
Recruiting
850 enrolled
Evaluation for NCI Surgery Branch Clinical Research Protocols
Recruiting
7,000 enrolled
Harvesting Cells for Experimental Cancer Treatments
Enrolling by invitation
7,000 enrolled
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Recruiting
500 enrolled
PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor
Not yet recruiting
40 enrolled
Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
Withdrawn
DP-04
Recruiting
100 enrolled
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Recruiting
100 enrolled
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
Active not recruiting
72 enrolled
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recruiting
2,000 enrolled
iCaRe2
Recruiting
999,999 enrolled
ELEPHAS-05
Recruiting
2,000 enrolled
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Completed
135 enrolled
ELEPHAS-02
Recruiting
416 enrolled
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Recruiting
500 enrolled
NEUTROFLOW
Not yet recruiting
600 enrolled
PROPHETIC
Active not recruiting
10,000 enrolled
TraveraRTGx
Recruiting
200 enrolled
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
Enrolling by invitation
1,200 enrolled
SBRT
Completed
98 enrolled
ORACLE
Recruiting
2,020 enrolled
Pan-tumor MRD Study
Recruiting
1,350 enrolled
PARTNER
Recruiting
6,250 enrolled
SURVIMON
Active not recruiting
100,000 enrolled
Eligibility Screening for the NIH Intramural Research Program Clinical Protocols
Completed
19,522 enrolled
PREFER
Completed
1,429 enrolled
TasteSPICIER
Completed
101 enrolled
BEGIN
Recruiting
400 enrolled
MOHCCN-O
Recruiting
500 enrolled
OCTANE
Recruiting
10,000 enrolled
CANSI
Enrolling by invitation
30 enrolled
SkinHealth
Recruiting
420 enrolled
BESPOKE Study of ctDNA Guided Immunotherapy
Completed
290 enrolled
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed
484 enrolled
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Completed
1,189 enrolled
Quality of Life and Physical Fitness After Immune Checkpoint Inhibitors
Completed
134 enrolled
POINTING
Recruiting
3,500 enrolled
CER
Recruiting
15,000 enrolled
POSITive
Recruiting
265 enrolled
Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer
Completed
13 enrolled
NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts
Unknown
30 enrolled
CANINE
Unknown
500 enrolled
G-DEFINER
Completed
247 enrolled
Microbiome Immunotherapy Toxicity and Response Evaluation
Unknown
1,800 enrolled
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Terminated
22 enrolled
BIOMIS-Onco
Completed
50 enrolled
PARADIGM
Recruiting
800 enrolled
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
Unknown
200 enrolled
Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy
Terminated
98 enrolled